Skip Navigation

Find a Doctor

Find a Researcher

Researchers

Karthik S Suresh, M.D.

Photo of Dr. Karthik S Suresh, M.D.
  • Assistant Professor of Medicine
Male

Languages: English, Tamil

Expertise

General Internal Medicine

Research Interests

ROS signaling; endothelial cell biology; vascular biology; calcium signaling

Locations

Johns Hopkins Bayview Medical Center

4940 Eastern Avenue
301 Building, 1st Floor
Baltimore, MD 21224 map
Phone: 410-955-9441

Johns Hopkins University

1830 E. Monument St.
Interstitial Lung Disease Clinic, 5th Floor
Baltimore, MD 21287 map
Phone: 410-955-4176

Background

Dr. Karthik Suresh is an assistant professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical interest and expertise include general internal medicine, pulmonary / critical care medicine and pulmonary complications of chemo/immunotherapy.

He earned his B.S. and M.D. from the University of Louisville School of Medicine. He completed his residency at the Osler Medicine training program at Johns Hopkins, and performed a fellowship in Pulmonary / Critical Care Medicine at Johns Hopkins. 

...read more

Titles

  • Assistant Professor of Medicine

Departments / Divisions

Education

Degrees

  • MD, University of Louisville School of Medicine (2008)

Residencies

  • Johns Hopkins University School of Medicine / Internal Medicine (2011)

Fellowships

  • Johns Hopkins University School of Medicine / Pulmonary Medicine (2012)
  • Johns Hopkins University School of Medicine (2016)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2011)

Research & Publications

Lab

Our lab focuses on three major topics focused around mechanisms of microvascular endothelial cell (MVEC) dysfunction in the lung: ROS-induced Ca2+ signaling; mechanisms of checkpoint inhibitor toxicity; and MVEC mitochondrial structure/function/genomics

1. ROS-induced Ca2+ influx: Using endothelial cells (ECs) isolated from humans, mice and rats, as well as animal models of ALI and PAH, we investigate the role of elevated reactive oxygen species (ROS) and intracellular calcium in regulating disease-specific abnormalities in EC function. In ALI, we study signaling pathways governing formation of paracellular gaps between endothelial cells, which clinically leads to alveolar flooding and hypoxemia. For PAH, we study the effect of ROS and calcium signaling on EC migration and proliferation as it relates to formation of vaso-occlusive lesions in the distal arterioles of the lung, a known contributor to elevations in pulmonary artery pressures in this disease.

2. Mechanisms of checkpoint inhibitor toxicity: In collaboration with Dr. Jarushka Naidoo (Oncology) and Dr. Franco D'Alessio (Pulm/CC), we study clinical characteristics and biologic mechanisms of lung injury in patients who develop pneumonitis after receiving immune checkpoint inhibitors (ICIs) - termed checkpoint inhibitor pneumonitis (CIP). We are specifically interested in mechanisms of endothelial leak and alveolar inflammatory cell efflux in CIP.

3. Mitochondrial structure/function/genomics in PAH: We are interested in the impact of abnormal mitochondrial structure (e.g. increased fragmentation), function (changes in respiration and metabolism) and genomics (induction of somatic mutations) on cytosolic Ca2+ levels and promotion of abnormal MVEC behavior (EndMT, migration, proliferation) in PAH.

Clinical Trial Keywords

ROS signaling, calcium signaling, microvascular endothelial cell physiology, mitochondrial structure/function, mechanisms of immunotherapy toxicity

Clinical Trials

 Optimization of steroid-refractory immune checkpoint inhibitors; Therapeutic options for autoimmune-associated interstitial lung disease

Selected Publications

Suresh K, Servinsky L, Jiang H, Bigham Z, Huetsch J, Kliment C, Damarla M, Shimoda LA "ROS-induced Ca2+ via TRPV4 and microvascular endothelial dysfunction in the SU5416/Hypoxia model of pulmonary arterial hypertension", Am J Physiol Lung Cell Mol Physiol. 314(5): L893-L907, 2018 (APSselect – April 2018)

Suresh K, Servinsky L, Jiang H, Bigham Z, Zaldumbide J, Huetsch J, Kliment C, Acoba M, Claypool S, Damarla M, Shimoda LA. "Mitochondrial ROS and Intracellular Ca2+ regulate mitochondrial morphology in microvascular endothelial cells isolated from the SU5416/Hypoxia rat model of pulmonary arterial hypertension" Am J Physiol Lung Cell Mol Physiol [Epub ahead of print] 2019

Suresh K, Zhong Q, Voong R, Ettinger D, Marrone K, Kelly R, Hahn C, Levy B, Feliciano J, Brahmer J, Forde P, Feller-Kopman D, Lerner A, Lee H, Yarmus L, D’Alessio F, Danoff S, Naidoo J. Pneumonitis in non–small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors, J. Thoracic Onc. 13: 1930-1939, 2018 (Editorial by Tay, et al: "Checkpoint Inhibitor Pneumonitis – Real World Incidence and Risk")

Suresh K, Psoter K, Shankar B, Voong R, Ettinger D, Marrone K, Kelly R, Hahn C, Levy B, Feliciano J, Brahmer J, Forde P, Feller-Kopman D, Lerner A, Lee H, Yarmus L, D’Alessio F, Danoff S, Naidoo J. Impact of checkpoint inhibitor pneumonitis on survival in non-small cell lung cancer patients receiving immune checkpoint immunotherapy, J. Thoracic Onc. 14: 494-502, 2019 (Editor’s Choice – JTO, March 2018; Editorial by Le et al: "Checkpoint inhibitor pneumonitis: Too clinically serious for benefit?")

Suresh K*, Naidoo J*, Zhong, Q, Xiong Y, Mammen J, Villegas de Flores M, Cappelli L, Balaji A, Palmer T, Anagnastou V, Ettinger D, Marrone K, Kelly R, Hahn C, Levy B, Feliciano J, Forde P, Feller-Kopman D, Lerner A, Lee H, Yarmus L, Shafiq M, Lipson E, Soloski M, Brahmer J, Danoff S, D’Alessio F. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis, J. Clin. Investig. [Epub ahead of print] 2019. * contributed equally.

Contact for Research Inquiries

Research Lab: Johns Hopkins Bayview
Asthma and Allergy Building, 4th floor
Baltimore, MD 21224 map

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button